Loading page...

Romanian Business News - ACTMedia :: Services|About us|Contact|RSS RSS


Ropharma estimates for this year an increase by 25% of the profit and by 5% of sales



The pharma company Ropharma Brasov (RPH) controlled by the businessman Mihai Miron, estimates for this year an increase by 25% of profit, at 9 million lei (two million euro) and by 5% ofsales, at 430 million lei (97 million euro).

The shareholders of Ropharma approved in AGM on Tuesday the budget of income and expenditure of the company.

Last year, the sales of the company increased insignificantly at 411.2 million lei (93 million euro) and the profit advanced by approximately 3% at 7.2 million lei (1.6 million euro).


Ropharma has two production units in Targu Mures and Kishinev where they produce food supplements and drugs. The distribution company has five warehouses and 1,200 drugstores. The drugstores chain includes 127 units. The covering area is 25 counties and the city of Bucharest.

The structure of sales was last year 71.4% through their own drugstores and 28.6% through distribution.

The company budgeted for this year investment of almost 7.2 million lei, out of which half for the acquisition of licences for drugstores. At the same time, the company has as a plan to launch 13 new products.

Ropharma is situated eighth in the top of national pharma distributors, with 3.3% market share, and on the retail sector is the fifth. The company has over 900 employees.

According to the most recent reports of BVB, the businessman Mihai Miron owns indirectly 31,65% of the Ropharma shares. Through Rimia Investments, he controls 14.12% of the shares, and through ADDPharmaceuticals 17.53%.

Arrow Pharmaceuticals, the registered company in the US controls 31.29% of the Ropharma shares.

In the Ropharma shareholders there is also the pensions fund AZT Viitorul Tau – Allianz which has 5.87% of the bonds, as well as the pensions fund ING with 4.99%.